Frankfurt - Delayed Quote EUR

Cellectar Biosciences, Inc. (NV4.F)

Compare
0.2160
+0.0160
+(8.00%)
As of 8:16:34 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
51,580.7510
38,960.6430
28,813.7730
24,131.2800
15,290.3490
Operating Income
-51,580.7510
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
Net Non Operating Interest Income Expense
1,105.8650
387.1470
152.5190
2.2840
10.8970
Other Income Expense
5,094.8050
-4,257.1140
-3,191.3640
6.6340
185.2800
Pretax Income
-45,380.0810
-42,830.6100
-31,852.6180
-24,122.3620
-15,094.1720
Tax Provision
--
-60.0000
-60.0000
--
--
Net Income Common Stockholders
-45,320.0810
-42,770.6100
-31,792.6180
-24,122.3620
-15,094.1720
Diluted NI Available to Com Stockholders
-52,603.8670
-42,770.6100
-31,792.6180
-24,122.3620
-15,094.1720
Basic EPS
-1.23
-3.50
-4.05
-4.30
-7.60
Diluted EPS
-1.41
-3.50
-4.05
-4.30
-7.60
Basic Average Shares
29,901.4780
12,221.5710
7,055.6650
5,551.5720
1,981.2650
Diluted Average Shares
30,422.7730
12,221.5710
7,055.6650
5,551.5720
1,981.2650
Total Operating Income as Reported
-51,580.7510
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
Total Expenses
51,580.7510
38,960.6430
28,813.7730
24,131.2800
15,290.3490
Net Income from Continuing & Discontinued Operation
-45,320.0810
-42,770.6100
-31,792.6180
-24,122.3620
-15,094.1720
Normalized Income
-58,158.1700
-38,988.8012
-35,419.3192
-24,122.3620
-15,279.4520
Interest Income
1,105.8650
387.1470
152.5190
2.2840
10.8970
Net Interest Income
1,105.8650
387.1470
152.5190
2.2840
10.8970
EBIT
-51,580.7510
-38,960.6430
-28,813.7730
-24,131.2800
-15,290.3490
EBITDA
-51,287.7090
-38,768.2680
-28,665.3380
-23,981.3650
-15,148.8960
Reconciled Depreciation
293.0420
192.3750
148.4350
149.9150
141.4530
Net Income from Continuing Operation Net Minority Interest
-45,320.0810
-42,770.6100
-31,792.6180
-24,122.3620
-15,094.1720
Total Unusual Items Excluding Goodwill
12,838.0890
-3,787.1140
3,633.2410
--
185.2800
Total Unusual Items
12,838.0890
-3,787.1140
3,633.2410
--
185.2800
Normalized EBITDA
-64,125.7980
-34,981.1540
-32,298.5790
-23,981.3650
-15,334.1760
Tax Rate for Calcs
--
0.0000
0.0000
--
--
Tax Effect of Unusual Items
--
-5.3052
6.5398
--
--
12/31/2020 - 12/8/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

8AW0.BE Ocean Biomedical Inc
0.1810
0.00%
 
2UV.DU Applied Therapeutics Inc
0.5570
-3.05%
 
2UV.F Applied Therapeutics, Inc.
0.5465
+6.12%
 
M55.F MacroGenics, Inc.
2.8800
-0.48%
 
0M4.DU Mersana Therapeutics Inc
0.6036
+2.20%
 
8AW0.F Ocean Biomedical, Inc.
0.1710
-22.27%
 
AT20.F Atara Biotherapeutics, Inc.
8.05
+8.05%
 
1VT.DU Viking Therapeutics Inc
32.57
+1.31%
 
3G0.BE Altimmune Inc
6.70
-0.21%
 
3G0.MU Altimmune Inc
6.67
+0.68%